Boston Scientific (NYSE:BSX) Price Target Lowered to $85.00 at Royal Bank Of Canada

Boston Scientific (NYSE:BSX) had its price objective lowered by equities researchers at Royal Bank Of Canada from $100.00 to $85.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Royal Bank Of Canada’s price target would indicate a potential upside of 90.17% from the company’s current price.

Several other analysts have also recently commented on the stock. Oppenheimer set a $90.00 price objective on shares of Boston Scientific in a research note on Thursday, April 23rd. Robert W. Baird set a $70.00 target price on shares of Boston Scientific in a research report on Thursday, May 28th. Daiwa Securities Group cut shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Zacks Research downgraded shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research report on Friday, June 5th. Finally, BTIG Research reissued a “buy” rating and set a $65.00 price target on shares of Boston Scientific in a research note on Tuesday, June 16th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $80.72.

Boston Scientific Price Performance

Shares of Boston Scientific stock traded down $0.07 during trading on Monday, reaching $44.70. The company’s stock had a trading volume of 1,202,586 shares, compared to its average volume of 17,975,367. The business has a 50 day moving average price of $49.41 and a 200-day moving average price of $67.50. Boston Scientific has a 12-month low of $42.25 and a 12-month high of $109.50. The company has a market capitalization of $66.44 billion, a P/E ratio of 18.84, a price-to-earnings-growth ratio of 0.86 and a beta of 0.58. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts anticipate that Boston Scientific will post 3.36 EPS for the current year.

Boston Scientific announced that its board has initiated a stock buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig acquired 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Cheryl Pegus bought 1,770 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ? increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 9,800 shares of company stock worth $554,012 over the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Boston Scientific

Large investors have recently bought and sold shares of the stock. Brighton Jones LLC raised its stake in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the period. FWL Investment Management LLC purchased a new stake in Boston Scientific during the 2nd quarter worth $26,000. Main Street Financial Solutions LLC increased its holdings in Boston Scientific by 35.3% in the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after purchasing an additional 1,971 shares in the last quarter. Ieq Capital LLC raised its position in Boston Scientific by 97.0% in the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after purchasing an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC lifted its stake in shares of Boston Scientific by 56.2% during the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after purchasing an additional 2,556 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.